In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Matinas BioPharma (MTNB), with a price target of $3.00. The company’s shares closed last Monday at $0.94.
According to TipRanks.com, McCarthy has 0 stars on 0-5 star ranking scale with an average return of -22.0% and a 25.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Hancock Jaffe Laboratories, Lineage Cell Therapeutics, and Actinium Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Matinas BioPharma with a $3.00 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $1.50 and a one-year low of $0.50. Currently, Matinas BioPharma has an average volume of 511K.
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of MTNB in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The company’s proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its anti-fungal product candidate, MAT2203, delivers broad-spectrum fungicidal agent, amphotericin B; and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded in May 2013 and is headquartered in Bedminster, NJ.
